Page 23 - BH-2-2

Brain & Heart Oxidative stress and neurological disorders

110. Radhakrishnan DM, Goyal V. Parkinson’s disease: [Alzheimer’s disease - diagnosis and treatment]. Tidsskr
A review. Neurol India. 2018;66(Suppl):S26-S35. Nor Laegeforen. 2021;141(7).
doi: 10.4103/0028-3886.226451 doi: 10.4045/tidsskr.20.0919
111. Pirker W, Katzenschlager R, Hallett M, Poewe W. 123. Stern Y. Cognitive reserve in ageing and Alzheimer’s
Pharmacological treatment of tremor in Parkinson’s disease. Lancet Neurol. 2012;11(11):1006-1012.
disease revisited. J Parkinsons Dis. 2023;13(2):127-144.
doi: 10.1016/S1474-4422(12)70191-6
doi: 10.3233/JPD-225060
124. Penney J, Ralvenius WT, Tsai LH. Modeling Alzheimer’s
112. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease with iPSC-derived brain cells. Mol Psychiatry.
disease. Lancet. 2021;397(10284):1577-1590. 2020;25(1):148-167.
doi: 10.1016/S0140-6736(20)32205-4 doi: 10.1038/s41380-019-0468-3
113. Weller J, Budson A. Current understanding of Alzheimer’s 125. Chen ZY, Zhang Y. Animal models of Alzheimer’s disease:
disease diagnosis and treatment. F1000Res. 2018;7:F1000 Applications, evaluation, and perspectives. Zool Res.
Faculty Rev-1161. 2022;43(6):1026-1040.
doi: 10.12688/f1000research.14506.1 doi: 10.24272/j.issn.2095-8137.2022.289
114. Khan S, Barve KH, Kumar MS. Recent advancements in 126. Sun BL, Li WW, Zhu C, et al. Clinical research on
pathogenesis, diagnostics and treatment of Alzheimer’s Alzheimer’s disease: Progress and perspectives. Neurosci
disease. Curr Neuropharmacol. 2020;18(11):1106-1125. Bull. 2018;34(6):1111-1118.
doi: 10.2174/1570159X18666200528142429 doi: 10.1007/s12264-018-0249-z
115. Breijyeh Z, Karaman R. Comprehensive review on 127. Toups K, Hathaway A, Gordon D, et al. Precision medicine
Alzheimer’s disease: Causes and treatment. Molecules. approach to Alzheimer’s disease: Successful pilot project.
2020;25(24):5789. J Alzheimers Dis. 2022;88(4):1411-1421.
doi: 10.3390/molecules25245789 doi: 10.3233/JAD-215707
116. Bondi MW, Edmonds EC, Salmon DP. Alzheimer’s disease: 128. Ma C, Hong F, Yang S. Amyloidosis in Alzheimer’s disease:
Past, present, and future. J Int Neuropsychol Soc. 2017;23(9- Pathogeny, etiology, and related therapeutic directions.
10):818-831. Molecules. 2022;27(4):1210.
doi: 10.1017/S135561771700100X doi: 10.3390/molecules27041210
117. Graff-Radford J, Yong KXX, Apostolova LG, et al. New 129. Liu S, Gao J, Zhu M, Liu K, Zhang HL. Gut microbiota
insights into atypical Alzheimer’s disease in the era of and dysbiosis in Alzheimer’s disease: Implications
biomarkers. Lancet Neurol. 2021;20(3):222-234. for pathogenesis and treatment. Mol Neurobiol.
2020;57(12):5026-5043.
doi: 10.1016/S1474-4422(20)30440-3
doi: 10.1007/s12035-020-02073-3
118. Briggs R, Kennelly SP, O’Neill D. Drug treatments in
Alzheimer’s disease. Clin Med (Lond). 2016;16(3):247-253. 130. Beata BK, Wojciech J, Johannes K, Piotr L, Barbara M.
Alzheimer’s disease-biochemical and psychological
doi: 10.7861/clinmedicine.16-3-247
background for diagnosis and treatment. Int J Mol Sci.
119. Rostagno AA. Pathogenesis of Alzheimer’s disease. Int J 2023;24(2):1059.
Mol Sci. 2022;24(1):107.
doi: 10.3390/ijms24021059
doi: 10.3390/ijms24010107
131. Viña J, Escudero J, Baquero M, et al. Genistein effect on
120. Ferrari C, Sorbi S. The complexity of Alzheimer’s disease: cognition in prodromal Alzheimer’s disease patients. The
An evolving puzzle. Physiol Rev. 2021;101(3):1047-1081. GENIAL clinical trial. Alzheimers Res Ther. 2022;14(1):164.
doi: 10.1152/physrev.00015.2020 doi: 10.1186/s13195-022-01097-2
121. Stefaniak O, Dobrzyńska M, Drzymała-Czyż S, 132. Boespflug EL, Eliassen JC, Dudley JA, et al. Enhanced
Przysławski J. Diet in the prevention of Alzheimer’s neural activation with blueberry supplementation in mild
disease: Current knowledge and future research cognitive impairment. Nutr Neurosci. 2018;21(4):297-305.
requirements. Nutrients. 2022;14(21):4564.
doi: 10.1080/1028415X.2017.1287833
doi: 10.3390/nu14214564
133. Gonzales MM, Garbarino VR, Marques Zilli E, et al.
122. Knapskog AB, Engedal K, Selbæk G, Øksengård AR. Senolytic therapy to modulate the progression of
Alzheimers sykdom - diagnostikk og behandling Alzheimer’s disease (SToMP-AD): A pilot clinical trial.

Volume 2 Issue 2 (2024) 17 doi: 10.36922/bh.2704